Enhertu approved in US for HER2-mutant NSCLC
12 August 2022 07:00 BST Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo's Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (